PURPOSE: In the recent years, nanotechnology has boosted the development of potential drug delivery systems and material engineering on nanoscale basis in order to increase drug specificity and reduce side effects. A potential delivery system for immunostimulating agents such as cytosine-phosphate-guanine-oligodeoxynucleotides (CpG-ODN) needs to be developed to maximize the efficacy of immunotherapy against hypersensitivity. In this study, an aerosol formulation of biodegradable, biocompatible and nontoxic gelatin nanoparticle-bound CpG-ODN 2216 was used to treat equine recurrent airway obstruction in a clinical study. METHODS: Bronchoalveolar lavage fluid was obtained from healthy and allergic horses to quantify Th1/Th2 cytokine levels before and after inhalation regimen. Full clinical examinations were performed to evaluate the therapeutic potential of this nebulized gelatin nanoparticle-based CpG formulation. RESULTS: Most remarkable was that regulatory anti-inflammatory and anti-allergic cytokine IL-10 expression was significantly triggered by five consecutive inhalations. Thorough assessment of clinical parameters following nanoparticle treatment indicated a partial remission of the allergic condition. CONCLUSION: Thus this study, for the first time, showed effectiveness of colloidal nanocarrier-mediated immunotherapy in food-producing animals with potential future applicability to other species including humans.
PURPOSE: In the recent years, nanotechnology has boosted the development of potential drug delivery systems and material engineering on nanoscale basis in order to increase drug specificity and reduce side effects. A potential delivery system for immunostimulating agents such as cytosine-phosphate-guanine-oligodeoxynucleotides (CpG-ODN) needs to be developed to maximize the efficacy of immunotherapy against hypersensitivity. In this study, an aerosol formulation of biodegradable, biocompatible and nontoxic gelatin nanoparticle-bound CpG-ODN 2216 was used to treat equine recurrent airway obstruction in a clinical study. METHODS: Bronchoalveolar lavage fluid was obtained from healthy and allergic horses to quantify Th1/Th2 cytokine levels before and after inhalation regimen. Full clinical examinations were performed to evaluate the therapeutic potential of this nebulized gelatin nanoparticle-based CpG formulation. RESULTS: Most remarkable was that regulatory anti-inflammatory and anti-allergic cytokine IL-10 expression was significantly triggered by five consecutive inhalations. Thorough assessment of clinical parameters following nanoparticle treatment indicated a partial remission of the allergic condition. CONCLUSION: Thus this study, for the first time, showed effectiveness of colloidal nanocarrier-mediated immunotherapy in food-producing animals with potential future applicability to other species including humans.
Authors: John Klier; Anna May; Sebastian Fuchs; Ulrike Schillinger; Christian Plank; Gerhard Winter; Heidrun Gehlen; Conrad Coester Journal: Vet Immunol Immunopathol Date: 2011-07-20 Impact factor: 2.046
Authors: Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester Journal: Pharm Res Date: 2007-10-03 Impact factor: 4.200
Authors: Kai Xiao; Juntao Luo; Wiley L Fowler; Yuanpei Li; Joyce S Lee; Li Xing; R Holland Cheng; Li Wang; Kit S Lam Journal: Biomaterials Date: 2009-08-05 Impact factor: 12.479
Authors: V Gerber; R Straub; E Marti; J Hauptman; C Herholz; M King; A Imhof; L Tahon; N E Robinson Journal: Equine Vet J Date: 2004-11 Impact factor: 2.888
Authors: G Senti; P Johansen; S Haug; C Bull; C Gottschaller; P Müller; T Pfister; P Maurer; M F Bachmann; N Graf; T M Kündig Journal: Clin Exp Allergy Date: 2009-02-16 Impact factor: 5.018
Authors: Andrew G Jarnicki; Helen Conroy; Corinna Brereton; Graham Donnelly; Deirdre Toomey; Kevin Walsh; Cheryl Sweeney; Olive Leavy; Jean Fletcher; Ed C Lavelle; Padraic Dunne; Kingston H G Mills Journal: J Immunol Date: 2008-03-15 Impact factor: 5.422
Authors: J Klier; B Lehmann; S Fuchs; S Reese; A Hirschmann; C Coester; G Winter; H Gehlen Journal: J Vet Intern Med Date: 2015-01 Impact factor: 3.333